Frog - Therein lies the difference in our world views and investment strategies...
You continue to believe DNAP is only a "pipedream"...
I continue to believe DNAP has a growing "drug pipeline"...
Biofontera's projects at the preclinical research stage include:
Cathepsin inhibitors
Inhibitors for protease activated receptors
Inhibitors for sphingomyelinase
Kinase inhibitors
Biofrontera's projects at the preclinical development stage include"
5-HT2B receptor inhibitor for migraine prophylaxis
Biofrontera's projects at the clinical development stage include:
Histidine decarboxylase inhibitor (Phase II)
Skin cancer drug (Phase II, inlicensing deal currently closed)
DNAPrint's projects include
Ovanome - Taxol/Carboplatin efficacy
Statnome - Lipitor, Zocor, efficacy
Statnome Muscle - Lipitor, Zocor adverse myalgia response
Acenome - Enalapril, Lisinopril efficacy
Acenome Musc - Enalapril, Lisinopril adverse cough
Immunosuppressants - Sirolimus, Tacrolimus, Mycophenolate mofetil efficacy in transplant patients
DNAP/Moffitt projects:
1) Response of Metastatic Colorectal Cancer to Irinotecan/Capecitabine (Xeliri) and Oxaliplatin/Capecitabine (Xelox)
2) Melphalan and Topotecan (MT) efficacy for treatment of Multiple Myeloma
3) Cyclophosphamide efficacy
4) Organistron adverse events - post operative nausea and vomiting
5) Esophageal malignancy chemotherapy response - standard FDA treatment
---------------------
While these may be "pipedreams" to you, they are real research projects leading to new drugs and drug classifiers...a VERY substantial "drug pipeline" for DNAP and all us DNAP investors...
Obviously we continue to see (and value) the world differently...and that's ok...
On the other hand, in spite of your pessimism and constant doom and gloom about DNAP....you ARE still here after 4 years.
I take that as a very good sign that DNAP offers you something for you to stick around so long...
I wish you as much success with your "pipedreams" as I do for DNAP's "drug pipeline"...
Take care,
Robert